EGFR and non-small cell lung carcinoma: This study was performed on a panel of osimertinib-resistant (OR) NSCLC cells originated from EGFR-mutated PC9 and PC9T790M osimertinib-sensitive (OS) cells after long-term treatment with osimertinib.